Testing BMS-986504 for Unresectable Nerve Sheath Tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This study tests whether a new drug called BMS-986504 is safe and effective for treating malignant peripheral nerve sheath tumors (MPNST) that cannot be surgically removed. The drug targets a specific genetic change (MTAP deletion) found in these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of MPNST (a type of nerve tumor) that cannot be surgically removed
- Your tumor has a specific genetic change called homozygous MTAP deletion, confirmed by genetic testing
- Your tumor can be measured by CT or MRI scans to track how it responds to treatment
- You are at least 12 years old and able to swallow tablets
- Your blood counts and organ function (liver, kidney) are close to normal or only mildly affected
- You have recovered from side effects of any previous cancer treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial collects tissue samples from people with MPNST or neurofibroma during surgery to find metabolic markers that could help diagnose MPNST faster and ensure complete removal of tumors.
This Phase 2 trial studies ASTX727 in people with malignant peripheral nerve sheath tumors (MPNST) that have a specific genetic change (“PRC2 loss”). It aims to shrink or control advanced tumors that have not responded to at least one standard treatment, by testing how well the drug works and is tolerated.
This study tests a new drug, BMS-986504, to see how it is processed and removed from the body in people with certain advanced solid tumors. It is for patients whose cancer has a specific genetic change (MTAP deletion) and who have no other good treatment options.
This trial tests two drugs, avutometinib and defactinib, given together to treat a rare type of nerve tumor (MPNST) that has come back or spread. The goal is to see if this combination can shrink or control the tumor.
This trial tests two targeted drugs, mirdametinib and vorinostat, to see if they can shrink MPNST tumors in people with NF1 before surgery. It is for patients whose tumors lack a specific protein marker (H3K27me3).
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
Hear when a new Malignant Peripheral Nerve Sheath Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.